Investigating the role of fortilin and CTNNA3 in heart failure
Fortilin, CTNNA3, and the Heart
This study is looking at how a protein called fortilin affects heart health and its connection to another protein that might play a role in heart failure, with the goal of finding new ways to help people with this serious condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10812215 on NIH RePORTER |
What this research studies
This research focuses on understanding how the protein fortilin affects heart function and its relationship with CTNNA3, a protein that may contribute to heart failure (HF). Researchers will study heart-specific knockout mice that lack fortilin to determine if low levels of this protein lead to increased degradation of CTNNA3 and subsequent heart failure. By analyzing heart tissue samples and using advanced techniques like microarray analyses, the team aims to uncover new molecular targets for treating HF. This could lead to innovative therapies for patients suffering from this progressive and often fatal condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure, particularly those experiencing severe symptoms.
Not a fit: Patients with heart failure who do not have low levels of fortilin or CTNNA3 may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow or reverse the progression of heart failure, improving survival rates and quality of life for patients.
How similar studies have performed: While previous attempts to treat heart failure through other molecular targets have been unsuccessful, this approach is novel and aims to explore untested pathways.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Fujise, Ken — University of Washington
- Study coordinator: Fujise, Ken
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.